Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
Targets |
Kd: 23 nM (cavolin-1)[1]
|
---|---|
ln Vitro |
Caveolin-1, or CAV, is a monotonic membrane protein with a molecular weight of 22 kDa. It only crosses one lipid bilayer leaflet, and its N- and C-termini stay on the cytoplasmic side. When multiple CAV copies oligomerize, they can create large molecular weight complexes that bend the membrane inward and create invaginations, or "caveolae," that are between 50 and 100 nm in diameter. A 36-amino acid peptide called T20 is extracted from gp41 and prevents HIV virus from fusing with CD4+ T cells. Compared to the original T20 parent sequence, WL47 is 7500 times more soluble and 80% shorter in length. WL47 activity demonstration in vitro using CAV oligomers and a technique for oligomerization degree measurement. Deoligomerization by WL47 is investigated using a version of CAV (CAV(FLV)) that oligomerizes spontaneously to generate CAV nanoparticles with diameters. In the presence of a reducing agent, WL47 does not effectively disrupt oligomerization, indicating that dimerization by disulfide bond is necessary for WL47 activity.
|
References |
[1]. Amanda J H Gilliam,et al. Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization. J Med Chem. 2016 Apr 28;59(8):4019-25.
|
Molecular Formula |
C82H131N24F3O29S4
|
---|---|
Related CAS # |
WL47
|
Appearance |
Typically exists as solid at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO :~50 mg/mL (~25.74 mM)
H2O :~33.33 mg/mL (~17.16 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (1.29 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.